Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.66 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.48 |
| ▸ | CASP3 | P42574 | 2/20 | 0.43 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.42 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.42 |
| ▸ | FABP7 | O15540 | 1/20 | 0.41 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.41 |
| ▸ | TGM2 | P21980 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7403546 | 0.96 | KMT2A (0.68) | KMT2AEPHX2CASP3FABP7FABP5 | |
| SCHEMBL6285024 | 0.95 | KMT2A (0.70) | KMT2AEPHX2CASP3FABP7FABP5 | |
| SCHEMBL7402295 | 0.92 | KMT2A (0.62) | KMT2AEPHX2CASP3FABP7FABP5 | |
| SCHEMBL571382 | 0.88 | KMT2A (0.67) | KMT2AEPHX2CASP3FABP7FABP5 | |
| SCHEMBL17130452 | 0.88 | KMT2A (0.60) | KMT2AEPHX2CASP3FABP7FABP5 | |
| SCHEMBL793384 | 0.86 | KMT2A (0.85) | KMT2AEPHX2CASP3FABP7FABP5 | |
| SCHEMBL10149864 | 0.86 | KMT2A (0.48) | KMT2AEPHX2CASP3FABP7FABP5 | |
| SCHEMBL7595024 | 0.85 | KMT2A (0.70) | KMT2AEPHX2CASP3FABP7FABP5 | |
| SCHEMBL8273302 | 0.85 | KMT2A (0.63) | KMT2AEPHX2CASP3FABP7FABP5 | |
| SCHEMBL4983472 | 0.85 | KMT2A (0.70) | KMT2AEPHX2CASP3FABP7FABP5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2901160-B1 | METHOD FOR SPECIFICALLY DETECTING A MATRIX METALLOPROTEINASE (MMP) WHICH IS ONLY OF INTEREST IN THE ACTIVE FORM THEREOF, IN A SAMPLE | COMMISSARIAT À L EN ATOMIQUE ET AUX EN ALTERNATIVES (FR) | 2016-10-19 | — | — | EP | disclosed |
| EP-0828737-A1 | ISOXAZOLINE AND ISOXAZOLE DERIVATIVES AS INTEGRIN RECEPTOR ANTAGONISTS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1998-03-18 | — | — | EP | disclosed |
| US-5710159-A | IMIDAZOLIN-2-YLAMINOPROPOXY)ISOXAZOL-5-CARBONYLAMINO-2 -BENZYLOXYCARBONYLAMINOPROPIONIC ACID AS ANTIINFLAMMATORY AGENTS, BONE DEGRADATION, TUMORS, METASTASES AND THROMBOSIS | THE DUPONT MERCK PHARMACEUTICAL COMPANY (US) | 1998-01-20 | — | — | US | disclosed |
| WO-1996037492-A1 | ISOXAZOLINE AND ISOXAZOLE DERIVATIVES AS INTEGRIN RECEPTOR ANTAGONISTS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1996-11-28 | — | — | WO | disclosed |